GSA Capital Partners’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

GSA Capital Partners’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-262,544	Closed	-$394K	–	2119
2018 Q1	$394K	Sell	262,544 -131,500	-33%	-$230K	0.02%	1184
2017 Q4	$560K	Sell	394,044 -74,751	-16%	-$123K	0.03%	885
2017 Q3	$1.07M	Sell	468,795 -73,000	-13%	-$97.7K	0.07%	481
2017 Q2	$731K	Buy	541,795 +254,400	+89%	+$367K	0.05%	764
2017 Q1	$615K	Buy	287,395 +115,400	+67%	+$434K	0.03%	972
2016 Q4	$758K	Sell	171,995 -95,200	-36%	-$452K	0.05%	721
2016 Q3	$1.3M	Buy	267,195 +174,800	+189%	+$797K	0.07%	461
2016 Q2	$305K	Buy	92,395 +33,100	+56%	+$125K	0.02%	1374
2016 Q1	$210K	Buy	+59,295	New	+$306K	0.01%	1469

Other funds holding ARLZ

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Salzhauer Michael $292M AUM 30% 1-Year Est. Return

PCM

PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

SCP

Silverleafe Capital Partners Germantown, Tennessee $367M AUM 37.49% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

GSA Capital Partners's ARLZ Position: Q2 2018 in Review

GSA Capital Partners sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q2 2018, closing a stake of 262,544 shares — an estimated $394K sold.

GSA Capital Partners first reported a position in ARLZ in Q1 2016 and held it in 9 quarters. The position peaked at $1.3M in Q3 2016. 48 funds tracked by Wall St. Rank hold ARLZ as of Q2 2018.

GSA Capital Partners reported no remaining Aralez Pharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
GSA Capital Partners sold 262,544 Aralez Pharmaceuticals Inc. shares in Q2 2018, an estimated $394K.
GSA Capital Partners first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 9 quarters.
GSA Capital Partners's Aralez Pharmaceuticals Inc. position peaked at $1.3M in Q3 2016.
48 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q2 2018.

Based on GSA Capital Partners's 13F filing for Q2 2018, filed 9 Aug 2018.